Sign In
Buy STIM
$1.20
-0.0300 (-2.44%)
At Close: Jun 22, 2026
Neuronetics, Inc. (STIM) Q4 2024 Earnings Call Transcript
09:52am, Tuesday, 04'th Mar 2025
Neuronetics, Inc. (NASDAQ:STIM ) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & Chief Executive Officer
Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
07:10am, Tuesday, 04'th Mar 2025
MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 03'rd Mar 2025
MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve t
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 07'th Feb 2025
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve th
Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock
07:54am, Friday, 07'th Feb 2025
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced that it has priced its previously announced underwritten public offering of its com
Neuronetics Announces Launch of Underwritten Public Offering of Common Stock
04:23pm, Thursday, 06'th Feb 2025
MALVERN, Pa., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced that it has commenced an underwritten public offering of its common stock. In conne
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression
08:31am, Wednesday, 29'th Jan 2025
Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools Advancing mental health treatment through innovative research, offering insig
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 18'th Dec 2024
MALVERN, Pa., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to a new employee as described below. In accordan
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 16'th Dec 2024
MALVERN, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to new employees as described below. In accordanc
Neuronetics and Greenbrook TMS Announce Closing of Transaction
10:00am, Tuesday, 10'th Dec 2024
MALVERN, Pa. and TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics”) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) (“Greenbrook”, and together with Neuroneti
Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
08:30am, Wednesday, 20'th Nov 2024
MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life
Neuronetics, Inc. (STIM) Q3 2024 Earnings Call Transcript
08:41pm, Tuesday, 12'th Nov 2024
Neuronetics, Inc. (NASDAQ:STIM ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President and Chief Executive Officer Steve
CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
06:45pm, Tuesday, 12'th Nov 2024
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Neuronetics, Inc. (NASDAQ: STIM), please note that in the second paragraph of the "Stockh
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 12'th Nov 2024
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve th
Neuronetics (STIM) Reports Q3 Loss, Lags Revenue Estimates
09:21am, Tuesday, 12'th Nov 2024
Neuronetics (STIM) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.33 per share a year ago.
